



Cellular Fibronectin ELISA kit

Fibronectins (Fns) are large glycoproteins present in both insoluble form in extra cellular matrix (ECM) and soluble form in various body fluids. The insoluble form is called cellular fibronectin (cFn) and the soluble form plasma fibronectin (pFn). (1)

Cellular Fibronectin (cFn) in citrate plasma is a marker for

- Tumors (non-specific) (2,3)
- Risk of vascular complications, especially in diabetes (4)
- Risk of stroke recurrence (5)
- Safety of thrombolytic therapy in stroke. Elevated levels of cFn in plasma have been shown to be associated with increased risk of hemorrhagic transformation after treatment with tissue plasminogen activator (t-PA) (6-7).

Cellular Fibronectin (cFn) in cervicovaginal fluid is a marker for

- Risk of premature birth (8-11)

Ordering details:

Cat. No.	Item
603 010	Cellular Fibronectin ELISA kit, Reseach Use Only

References:

1. Ruoslahti E. Fibronectin and its receptors. *Ann Rev Biochem* 1988; 57:375-413
2. Yläupa S, Haglund C, Mertaniemi P et al. Cellular fibronectin in serum and plasma. A potential new tumor marker? *Br J Cancer* 1995; 71:578-582.
3. Haglund C, Yläupa S, Mertaniemi P, Partanen P. Cellular fibronectin concentration in the plasma of patients with malignant and benign diseases. A comparison with CA 19-9 and CEA. *Br J Cancer* 1997; 76:777-783
4. Kanters SD, Banga JD, Algra A et al. Plasma levels of cellular fibronectin in diabetes. *Diabetes Care* 2001; 24: 323-7.
5. Serena J, Blanco M, Castellanos M et al. The prediction of malignant cerebral infarction by molecular brain barrier disruption markers. *Stroke* 2005; 36: 1921-1926.
6. Castellanos M, Leira R, Serena J et al. Plasma cellular-fibronectin concentration predicts hemorrhagic transformation after thrombolytic therapy in acute ischemic stroke. *Stroke* 2004; 35: 1671-6.
7. Castellanos M, Sobrino T, Millan M et al. Serum Cellular Fibronectin and Matrix Metalloproteinase-9 as Screening Biomarkers for the Prediction of Parenchymal Hematoma After Thrombolytic Therapy in Acute Ischemic Stroke. A Multicenter Confirmatory Study. *Stroke* 2007 May 3; [Epub ahead of print].
8. Honest H, Bachmann LM, Gupta JK et al. Accuracy of cervicovaginal fetal fibronectin test in predicting risk of spontaneous preterm birth: systematic review. *BMJ*. 2002; 325: 301-11.
9. Iams JD, Casal D, McGregor JA et al. Fetal fibronectin improves the accuracy of diagnosis of preterm labor. *Am J Obstet Gynecol* 1995; 173: 141-5.
10. Joffe GM, Jacques D, Bemis-Heys R et al. Impact of the fetal fibronectin assay on admissions for preterm labor. *Am J Obstet Gynecol* 1999; 180: 581-6.
11. Peaceman AM, Andrews WW, Thorp JM et al. Fetal fibronectin as a predictor of preterm birth in patients with symptoms: a multicenter trial. *Am J Obstet Gynecol* 1997; 177: 13-8.

